Tempus AI

Sources - 28

Every claim above cites one of these, or states the reasoning that derived it. The quote is frozen at the date it was read: a link can rot, and an agent fetch returns a reading of a page rather than the page. Backs counts the whole claim ledger, so it can name a claim this page does not surface.

1. S01primarycompany filing2026-02-24
   Form 10-K for the fiscal year ended December 31, 2025
   Item 1 business and competition, the related-party note, reimbursement and payer detail, oncology sample volume, the Illumina dependency, risk factors
   backsC01C02C08C10C12C15C16C17C18C21C22C23C24C25C43C44C45C48C49C55C56C61C62C66C67C68
2. S02primarycompany release2026-02-24
   Q4 and full year 2025 results release, Exhibit 99.1 to Form 8-K
   the organic growth figure excluding Ambry, product-line revenue splits, adjusted EBITDA, remaining contract value, net revenue retention and the first 2026 guidance
   backsC02C03C14C15
3. S03primarycompany filing2026-07-30
   Form 10-Q for the quarter ended June 30, 2026
   the income statement and balance sheet, the related-party note, the convertible note terms, the Ambry and Paige purchase accounting, the Personalis subsequent event
   backsC04C05C06C07C09C10C11C12C13C25C27C28C29C30C31C32C40C56C61C66C68
4. S04primarycompany release2026-07-30
   Q2 2026 results release, Exhibit 99.1 to Form 8-K
   raised 2026 guidance, the unrealised-gain figure inside net income, oncology and MRD volume growth, bookings, cash and marketable securities
   backsC04C06C07C09C13C22C26C28C29C30C36C40C46
5. S05primarycompany release2026-07-20
   Personalis merger announcement, Exhibit 99.1 to Form 8-K
   the price per share, the enterprise value, the all-stock structure, the maximum exchange ratio and the $46.00 termination floor
   backsC32
6. S06primarytranscript2026-05-05
   Q1 2026 earnings call transcript
   management's three-year growth framing, the minimal-residual-disease unit economics, the algorithm attach rate; and nine analyst questions, none of which raised the related-party share of data revenue
   backsC41C46
7. S07secondaryvendor data2026-09-26
   Research pack for TEM, frozen at content/TEM/research-pack.json (refreshed 2026-09-26)
   price (the 25 September 2026 close of $85.01), enterprise value, the twenty-day range, returns, the analyst split, insider filings and the filed competitor cohort's multiples
   backsC35C39C40C42C53
8. S08primarygovernment data2026-08-25
   NCI Surveillance, Epidemiology and End Results Program - Cancer Stat Facts: Cancer of Any Site National Cancer Institute
   the base for the prize, counted in patients by a body with no interest in the answer

   In 2026, it is estimated that there will be 2,114,850 new cases of cancer of any site

   backsC19
9. S09primaryindustry data2026-07-29
   Kang S-Y, Zhang R, Kim C, et al. Genomic Testing Uptake Among Medicare Beneficiaries With Cancer. JAMA Network Open JAMA Network Open
   how far this market actually is from the narrative, measured on government claims data by researchers with no position in it

   Of 391 151 Medicare beneficiaries with cancer (50.6% were female; 31.8% were older than 75 years), 7.0% received non-NGS testing only, 1.2% NGS only, 0.5% both, and 91.4% no genomic testing. NGS adoption increased modestly, whereas overall genomic testing nearly tripled from 6.0% in 2016 to 16.7% in 2023.

   backsC20
10. S10primaryregulator2020-01-27
    CMS National Coverage Determination 90.2 - Next Generation Sequencing Centers for Medicare & Medicaid Services
    the regulatory gate that decides which sequencing tests Medicare pays for, and therefore why the FDA approvals matter

    The diagnostic laboratory test using NGS must have: Food & Drug Administration (FDA) approval or clearance as a companion in vitro diagnostic; and, an FDA-approved or -cleared indication for use in that patient's cancer

    backsC21
11. S11primarycompany filing2026-03-03
    Caris Life Sciences Form 10-K for the fiscal year ended December 31, 2025 Caris Life Sciences, Inc.
    a direct rival's own naming of Tempus as a competitor, and its own tissue-profiling case volume - an outside measure of relative scale
    backsC23C24C55
12. S12primarycompany filing2026-02-26
    Personalis Form 10-K for the fiscal year ended December 31, 2025 Personalis, Inc.
    what Tempus is buying: revenue, its direction, the losses, the clinical test business and the Moderna concentration
    backsC33C34
13. S13primarycompany release2026-08-19
    Merck and Moderna announce Phase 3 INTerpath-001 trial results Merck & Co., Inc.
    the third-party event behind the August share-price move, from the parties that ran the trial

    Intismeran autogene is an mRNA-based individualized neoantigen therapy (INT) designed specifically for each patient based on the unique set of mutations within their tumor

    backsC35
14. S14primarycompany filing2026-08-20
    Form 4 - Eric P. Lefkofsky, transactions of 18 August 2026
    the transaction code and the footnote saying the sale was issuer-mandated to fund tax withholding, plus the indirect holdings the aggregate hides
    backsC42
15. S15primarycompany filing2026-08-20
    Form 4 - Thomas Edward Schoenherr, transactions of 18-19 August 2026
    the second footnote: a Rule 10b5-1 plan adopted eleven months before the sales it executed
    backsC42
16. S16primarycompany filing2026-02-27
    Natera Form 10-K for the fiscal year ended December 31, 2025 Natera, Inc.
    the scale of the incumbent in tumour-informed recurrence monitoring, in revenue and in tests processed
    backsC47
17. S17primarycompany filing2026-09-21
    Recursion Pharmaceuticals Form 8-K, Item 1.01 - amendment to the Tempus Master Agreement and RNA foundation model licence Recursion Pharmaceuticals, Inc.
    the counterparty's own account of the 15 September 2026 amendment: the original fee schedule, the cut to $14M a year, the removal of the termination right, fewer data records, and the $12M Tempus pays back for Recursion's model
    backsC50
18. S18primarycompany filing2026-08-31
    Tempus Form S-4 registration statement for the Personalis merger (accession 0001193125-26-376895)
    read in full at the 2026-09-25 review: the merger consideration, exchange ratio, $48.42 floor and $46.00 walk-away, the cash election and its 40% stock minimum, Tempus's 13,039,067 Personalis shares and Personalis's 106,875,990 shares outstanding, Tempus's 181.6 million shares outstanding, the financing of any cash election, the conditions, outside date, antitrust remedy commitment and termination fees, the merger agreement's statement of Tempus's capital (21,102,107 shares reserved for the convertible notes), the merger-specific risk factors, the commercialization agreement, Tempus management's own projections for Personalis as a subsidiary to 2040 with Morgan Stanley's valuation of them, Personalis's projections, and the bidding history. It carries no pro forma combined financial statements.
    backsC32C51C53
19. S19primarycompany filing2026-09-15
    Tempus Form 425 - transcript of the chief executive at the Morgan Stanley Global Healthcare Conference, 15 September 2026
    the chief executive's statements on Medicare pricing for the tumour-only test and the liquid biopsy, the Merck-Moderna rollout, data bookings, and the gap between the two sets of Personalis projections
    backsC52
20. S20primaryvendor data2026-09-24
    FMP end-of-day price history for TEM, 20 July to 24 September 2026
    the 24 September 2026 close of $82.24 at which the Personalis exchange ratio and the notes' conversion prices are read
    read, but no claim rests on it
21. S21primarycompany filing2026-09-24
    Form 4 filings for Tempus insiders, 21 August to 24 September 2026, read through scripts/insider_fetch.py for the Rule 10b5-1 flag
    the Rule 10b5-1 box on every open-market sale filed after 20 August 2026, including the chief executive's sales of 25 August, 17 September and 22 September
    backsC42
22. S22primarycompany filing2025-06-20
    Caris Life Sciences final IPO prospectus (Form 424B4), market opportunity section citing a Nephron Research market study Caris commissioned Caris Life Sciences, Inc.
    an analyst's sizing, filed by a rival, of the US therapy-selection market in patient profiles a year and its price, and of the US biopharma data-services market
    backsC54
23. S23primarycompany filing2026-02-19
    Guardant Health Form 10-K for the fiscal year ended December 31, 2025 Guardant Health, Inc.
    a direct rival's own oncology test volume, oncology revenue and biopharma and data revenue for 2025 and 2024
    backsC55
24. S24primarycompany filing2026-02-24
    Myriad Genetics Form 10-K for the fiscal year ended December 31, 2025 Myriad Genetics, Inc.
    the largest hereditary-cancer rival's revenue, volume and price change for 2025
    backsC57
25. S25secondarynews2026-03-12
    The Imaging Wire - FDA Updates AI List with New Clearances (12 March 2026), reporting the FDA's list of AI-enabled medical devices through December 2025 The Imaging Wire
    the count of FDA-authorised AI devices and radiology's share, read through press_fetch because www.fda.gov refuses this repository's fetcher; a pointer to the FDA list, not the list itself

    Authorized 1,451 AI-enabled medical devices since it began keeping track in 1995. Approved 1,104 radiology devices, or 76% of total AI-enabled medical authorizations.

    backsC58
26. S26secondaryvendor data2026-10-01
    FMP key-metrics TTM, quote and annual analyst estimates for TEM, MYGN, NEO, WGS, CAI, GH and NTRA, fetched 2026-10-01 through scripts/api/fmp.py Financial Modeling Prep
    each filed competitor's enterprise value against trailing revenue and against consensus revenue for 2026 to 2029
    backsC59
27. S27primarycompany filing2026-04-07
    Tempus AI proxy statement (DEF 14A), filed April 7, 2026, for the May 21, 2026 annual meeting
    beneficial ownership and voting power as of March 27, 2026; executive officers' tenure; the 2025 bonus goals and payout; the 2025 PSU metrics and first-tranche result; the summary compensation table
    backsC62C63C64C65
28. S28primarycompany filing2026-10-02
    Tempus Form S-4/A for the Personalis merger, filed October 2, 2026 (accession 0001193125-26-412289)
    the expected closing window (late 2026 or early 2027) and the outside date of April 20, 2027 with its automatic extensions
    backsC69